Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lasmiditan Co-administered With Topiramate in Healthy Subjects
NCT03308669Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing Lasmiditan + Topiramate with Placebo + Topiramate (2 arms). Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Oct 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03308669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308669.